Kardium Enrolls First Patient in North American Globe Registry

Burnaby-based Kardium has enrolled the first patient in a new registry that will track how its Globe Pulsed Field System performs in routine clinical practice as adoption of the heart-treatment technology expands.

The Globe Registry is expected to enrol up to 500 patients across sites in Canada and the United States, with participants followed for 12 months after their procedures to evaluate treatment effectiveness. The observational study will assess the system’s safety and effectiveness in patients with atrial fibrillation.

Overlake Medical Center in Bellevue, Washington, enrolled the first patient. Dr. Maheer Gandhavadi, the centre’s medical director of electrophysiology, said early experience with the device has been encouraging, pointing to its mapping capabilities and ability to customize treatment.

“We’re hearing positive feedback from physicians who have used the device across a broad range of cases,” said Kardium CEO Kevin Chaplin. The registry will help the company collect evidence as use of the technology grows.

The Globe System combines high-density cardiac mapping and pulsed field ablation in a single catheter, allowing physicians to map the heart’s electrical activity and deliver targeted treatment through one device.

The announcement builds on a series of regulatory, financing, and manufacturing milestones previously covered by Techcouver.

The company secured U.S. Food and Drug Administration approval in 2025 and subsequently completed its first commercial procedures in the United States. Canadian approval followed this summer.

As Techcouver reported in August, Ottawa committed up to $31.25 million toward Kardium’s $125 million manufacturing expansion in British Columbia. The project is expected to increase annual production capacity from 500 units to 30,000 and create and maintain a total of 1,000 highly skilled jobs.

That expansion followed a US$250 million financing round in 2025 to support the Globe System’s commercial launch, manufacturing capacity, and commercial team.

With production scaling and commercial use underway, the registry adds a longer-term evidence-gathering component to Kardium’s rollout across North America.